These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38188466)

  • 1. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
    Bai Q; Shi X; Zhou X; Liang Z; Lu S; Wu Y
    Ther Adv Med Oncol; 2024; 16():17588359231216096. PubMed ID: 38188466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
    Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
    J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
    Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
    Front Oncol; 2021; 11():649766. PubMed ID: 34249687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features.
    Meng Y; Zhou W; Li C; Zhou X; Li X; Li L; Fu Q; Huang J; Yue Y; Shen X; Yang L; Wang M
    Front Oncol; 2024; 14():1383964. PubMed ID: 39015492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia.
    Mahrous M; Omar Jebriel A; Allehebi A; Shafik A; El Karak F; Venturini F; Alhusaini H; Meergans M; Ali Nahit Sendur M; Ouda M; Al-Nassar M; Kilickap S; Al Turki S; Al-Fayea T; Abdel Kader Y
    Cureus; 2023 Jul; 15(7):e41992. PubMed ID: 37492039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future treatment options for
    Hong L; Zhang J; Heymach JV; Le X
    Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
    Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
    Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration-A Narrative Review.
    Zhu X; Lu Y; Lu S
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
    Minne RL; Luo NY; Traynor AM; Huang M; DeTullio L; Godden J; Stoppler M; Kimple RJ; Baschnagel AM
    Clin Lung Cancer; 2024 Sep; 25(6):567-576.e1. PubMed ID: 38852006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Cancer with
    Fujino T; Suda K; Mitsudomi T
    Lung Cancer (Auckl); 2021; 12():35-50. PubMed ID: 34295201
    [No Abstract]   [Full Text] [Related]  

  • 14. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
    Ahn MJ; Mendoza MJL; Pavlakis N; Kato T; Soo RA; Kim DW; Liam CK; Hsia TC; Lee CK; Reungwetwattana T; Geater S; Chan OSH; Prasongsook N; Solomon BJ; Nguyen TTH; Kozuki T; Yang JC; Wu YL; Mok TSK; Tan DS; Yatabe Y
    Clin Lung Cancer; 2022 Dec; 23(8):670-685. PubMed ID: 36151006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
    Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
    Spitaleri G; Trillo Aliaga P; Attili I; Del Signore E; Corvaja C; Corti C; Uliano J; Passaro A; de Marinis F
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
    Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z
    Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
    Jamme P; Fernandes M; Copin MC; Descarpentries C; Escande F; Morabito A; Grégoire V; Jamme M; Baldacci S; Tulasne D; Kherrouche Z; Cortot AB
    J Thorac Oncol; 2020 May; 15(5):741-751. PubMed ID: 32169477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 
Skipping Mutation].
    Editorial Office of Chinese Journal of Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):416-428. PubMed ID: 37488079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.